What is InMed Pharmaceuticals Inc (INM) stock price today?

InMed Pharmaceuticals Inc (INM) currently trades at $0.70 per share. The stock has a market capitalization of $2.43M and a P/E ratio of —x.

Is INM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, InMed Pharmaceuticals Inc has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is InMed Pharmaceuticals Inc's revenue and earnings?

InMed Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $4.51M with profit margins of -170.10%. Earnings per share (EPS) is $-2.88.

INM

InMed Pharmaceuticals Inc

NASDAQ: INM · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$0.70

+0.00% today

Updated 2026-04-29

Market cap

$2.43M

P/E ratio

—

P/S ratio

0.54x

EPS (TTM)

$-2.88

Dividend yield

—

52W range

$1 – $6

Volume

0.1M

Market cap

$2.43M

P/E ratio

—

P/S ratio

0.54x

EPS (TTM)

$-2.88

Dividend yield

—

52W range

$1 – $6

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$20.00

+2753.07%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at -170.10%

- Negative free cash flow $-3.23M

- Revenue declining -26.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.09M	$4.14M	$4.60M	$4.94M	$4.51M
Net income	$-18.60M	$-7.95M	$-7.68M	$-8.16M	$-2.78M
EPS	—	—	—	—	$-2.88
Free cash flow	$-15.62M	$-7.45M	$-7.00M	$-7.77M	$-3.23M
Profit margin	-1,707.32%	-192.18%	-166.94%	-165.14%	-170.10%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INM	$2.43M	31	5.3	2.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

InMed Pharmaceuticals Inc trades at $0.70. Our Smart Value Score of 31/100 indicates the stock is weak. TTM revenue stands at $4.51M. with profit margins at -170.10%.

Frequently asked questions

What is InMed Pharmaceuticals Inc's stock price?

InMed Pharmaceuticals Inc (INM) trades at $0.70.

Is InMed Pharmaceuticals Inc overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of InMed Pharmaceuticals Inc (INM)?

The analyst target price is $20.00, representing +2753.1% upside from the current price of $0.70.

What is InMed Pharmaceuticals Inc's revenue?

TTM revenue is $4.51M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio0.54x

ROE-97.20%

Beta0.52

50D MA$0.78

200D MA$1.55

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

INM vs LLY →INM vs JNJ →INM vs ABBV →Stock screener →